The global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market has been witnessing robust growth, driven by an increasing incidence of lung diseases, a growing geriatric population, and heightened patient awareness. The market, valued at USD 3.59 billion in 2023, is expected to grow at a CAGR of 5.8% during the forecast period of 2024-2032, reaching an estimated USD 5.96 billion by...
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek